Patents Assigned to AstraZeneca
  • N-(-3-METHOXY-5-METHYLPYRAZIN-2-YL)-2-(4-'1,3,4-OXADIAZOL-2-YL!PHENYL)PYRIDINE-3 SULPHONAMIDE AS AN ANTICANCER AGENT
    Publication number: 20110003831
    Abstract: The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.
    Type: Application
    Filed: September 13, 2010
    Publication date: January 6, 2011
    Applicant: ASTRAZENECA AB
    Inventors: David Williams Tonge, Sian Tomiko Taylor, Francis Thomas Boyle, Andrew Mark Hughes, Donna Johnson, Marianne Bernice Ashford, Nigel Charles Barrass
  • 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
    Patent number: 7863265
    Abstract: Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    Type: Grant
    Filed: June 19, 2006
    Date of Patent: January 4, 2011
    Assignee: AstraZeneca AB
    Inventors: Susanne Alenfalk, Mikael Dahlstrom, Fana Hunegnaw, Staffan Karlsson, Malin Lemurell, Ann-Margret Lindqvist, Tore Skjaret, Ingemar Starke
  • Chemical process for preparation of intermediates
    Patent number: 7863469
    Abstract: The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure trans-cyclopropane carboxylic acid derivatives, processes for preparing the carboxylic acid derivatives and their use in preparing pharmaceuticals.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: January 4, 2011
    Assignee: AstraZeneca AB
    Inventors: Jean-Paul Dejonghe, Koen Peeters, Marc Renard
  • Antibodies Directed to Alpha V Beta 6 And Uses Thereof
    Publication number: 20100330103
    Abstract: Targeted binding agents, such antibodies directed to the antigen ?V?6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen ?V?6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
    Type: Application
    Filed: May 18, 2010
    Publication date: December 30, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Julie RINKENBERGER, Ian FOLTZ, Avril ALFRED, Simon Thomas BARRY, Vahe BEDIAN
  • Bis-(Sulfonylamino) derivatives for use in therapy
    Publication number: 20100331321
    Abstract: The invention provides compounds of formula (I) wherein R1,R3,L1,L2,G1,G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
    Type: Application
    Filed: December 18, 2008
    Publication date: December 30, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Johan Bylund, Maria E. Ek, Ylva Gravenfors, Jorg Holenz, Alexander Minidis, Gunnar Nordvall, Daniel Sohn, Karl S.A. Vallin, Jenny Viklund, Stefan Von Berg
  • 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774
    Publication number: 20100331341
    Abstract: The present invention relates to compounds of formula (I), wherein R1 is heteroaryl or heterocyclyl, optionally substituted; R2 is C1-4alkyl, heterocyclyl, C1-4alkylaryl, C1-4alkylheteroaryl, carbocyclyl, C1-4alkylheterocyclyl, heterocyclyl-heteroaryl, aryl-heterocyclyl, carbocyclyl-heteroaryl, heterocyclyl-aryl, optionally substituted; R3 is hydrogen or C1-4alkyl, or R2 and R3 may together with the nitrogen atom, form a saturated ring system containing 4, 5 or 6 ring forming atoms, and optionally substituted; R4 is hydrogen, halogen, methyl or methoxy; to pharmaceutical composition containing said compounds and to the use of said compounds in therapy, for instance in treating cognitive disorders. The present invention further relates to new intermediates useful in the preparation thereof.
    Type: Application
    Filed: June 28, 2010
    Publication date: December 30, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Johan ANDERSSON, Helena GYBÄCK, Anh JOHANSSON, Christian Erik LINDE, Jonas MALMSTRÖM, Gunnar NORDVALL, Tatjana WEIGELT, Gitte TERP
  • BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS
    Publication number: 20100331329
    Abstract: The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R2 is halo and n is 0-2; and each R4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by histone deacetylase.
    Type: Application
    Filed: September 10, 2010
    Publication date: December 30, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Elaine Sophie Elizabeth Stokes, Craig Anthony Roberts, Michael James Waring
  • Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer
    Publication number: 20100330179
    Abstract: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer.
    Type: Application
    Filed: June 24, 2010
    Publication date: December 30, 2010
    Applicants: ASTRAZENECA AB, POZEN INC.
    Inventors: Brian Ault, Clara Hwang, Everardus Orlemans, John R. Plachetka, Mark Sostek
  • Processes For The Preparation Of Optically Active Intermediates
    Publication number: 20100331575
    Abstract: This invention relates to processes for the production of optically active 2-(disubstituted aryl)cyclopropylamine compounds and optically active 2-(disubstituted aryl)cyclopropane carboxamide compounds which are useful intermediates for the preparation of pharmaceutical agents, and in particular the compound [1S-(1?,2?,3?(1S*,2R*),5?)]-3-[7-[2-(3,4-difluorophenyl)-cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol.
    Type: Application
    Filed: August 11, 2010
    Publication date: December 30, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Masaru Mitsuda, Tadashi Moroshima, Kentaro Tsukuya, Kazuhiko Watabe, Masahiko Yamada
  • Lactams and uses thereof
    Patent number: 7858776
    Abstract: Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid ? protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit ? secretase and thereby inhibit the production of amyloid ? protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: December 28, 2010
    Assignee: AstraZeneca AB
    Inventors: Bruce Thomas Dembofsky, Robert Jacobs, Cyrus Ohnmacht
  • Chemical Process
    Publication number: 20100324289
    Abstract: The present invention provides a process for the preparation of a compound of formula (I); wherein X is halogen; Y is ZR1; Z is oxygen or sulphur; and R1 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cloalkyl; the process comprising either: hydrogenating a compound of formula (II); with a suitable transition metal catalyst in a C1-6 aliphatic alcohol, an ether, an hydrocarbon as solvent; or, conducting a one-pot hydrogenation of a compound of formula (III): wherein R2 is phenyl optionally substituted by chloro, C1-6 alkyl, C1-6 alkoxy or (C1-6 alkyl)2N; firstly at about 20° C. to form a compound of formula (IV): and then at about 40° C.; both steps (I) and (ii) being carried out in the presence of a suitable catalyst and in the presence of a suitable solvent.
    Type: Application
    Filed: August 31, 2010
    Publication date: December 23, 2010
    Applicant: AstraZeneca AB
    Inventors: Ulf Larsson, Kajsa Rådevik
  • 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER
    Publication number: 20100324040
    Abstract: The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.
    Type: Application
    Filed: May 2, 2008
    Publication date: December 23, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Audrey Davies, Stephanos Ioannidis, Michelle Lamb, Mei Su, Tao Wang, Hai-Jun Zhang
  • PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS
    Publication number: 20100324072
    Abstract: This invention relates to novel compounds having the structural formula I below: (I) and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: May 14, 2008
    Publication date: December 23, 2010
    Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LTD.
    Inventors: Gianni Chessari, Miles Stuart Congreve, Jorg Holenz, Christopher Murray, Sahil Patel, Laszlo Rakos, Didier Rotticci
  • Process For Isolating Mono-Carboxy Substituted Probucol Derivatives
    Publication number: 20100324328
    Abstract: A process for isolating a compound of formula (I) or a salt thereof, where X and R1 are as defined in the specification, from a mixture containing it, and the corresponding diacid and dihydroxy derivative, said process comprising (i) adding to an organic solution containing said compounds, water and a one or more salts, all of which are bases selected from a carbonate or hydrogen carbonate base, (ii) separating the aqueous phase containing the compound of formula (II) from the organic phase containing the compounds of formula (I) and (III); then (iii) recovering the compound of formula (I) from remaining organic phase. The process provides for efficient isolation of the target compound, even on a large scale.
    Type: Application
    Filed: June 25, 2008
    Publication date: December 23, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Jeremy Stephen Parker, Evan William Snape
  • CHEMICAL COMPOUNDS 785
    Publication number: 20100324068
    Abstract: DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, r is 0 or 1 and X1 is linear (1-3C)alkyl; q is 0 or 1 and X2 is fluoro, chloro or (1-3C)alkyl; Y1 is selected from fluoro, chloro, bromo, cyano, (1-3C)alkyl and (1-2C)alkoxy; n is 0, 1 or 2 and Y2 is fluoro, chloro or (1-3C)alkyl; p is 0, 1 or 2 and Y3 is (1-3C)alkyl or forms a (3-5C)cycloalkyl ring; Z is carboxy or —CONHSO2Me or —CONRbRc wherein Rb and Rc are independently selected, for example, from hydrogen and (1-4C)alkyl or Rb and Rc are linked so as to form a morpholine ring or a (4-6C)heterocyclic ring and when Z is —CONRbRc the Rb and Rc groups may be optionally substituted by carboxy.
    Type: Application
    Filed: June 18, 2010
    Publication date: December 23, 2010
    Applicant: AstraZeneca AB
    Inventors: Alan Martin Birch, Roger John Butlin, Leonie Campbell, Clive Green, Andrew Leach, Michael James Waring, Paul Michael Murray, Per Olof Ryberg
  • Compounds
    Patent number: 7855213
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: December 21, 2010
    Assignees: AstraZeneca AB, Astex Therapeutics Ltd.
    Inventors: James Arnold, Phil Edwards, Mark Sylvester, Stefan Berg, Jörg Holenz, Annika Kers, Karin Kolmodin, Laszlo Rakos, Liselotte Öhberg, Rotticci Didier, Gianni Chessari, Miles Congreve, Christopher Murray, Sahil Patel
  • Raman spectroscopic method for determining the ratio of 5-methoxy and 6-methoxy isomers of omeprazole
    Patent number: 7855082
    Abstract: The present invention relates to a novel method to determine the ratio of 5-methoxy and 6-methoxy isomers of omeprazole present in a mixture thereof. The method uses different Raman scattering efficiency values for the 5-methoxy and 6-methoxy isomers. This is of importance since the two isomers have different stability in the solid state in bulk form and in admixture with pharmaceutical excipients.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: December 21, 2010
    Assignee: AstraZeneca AB
    Inventor: Frans Langkilde
  • OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS
    Publication number: 20100317653
    Abstract: Compounds of formula (I), and salts and pro-drugs thereof: wherein for example R1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.
    Type: Application
    Filed: August 3, 2010
    Publication date: December 16, 2010
    Applicant: AstraZeneca AB
    Inventors: Alan Martin BIRCH, Suzanne Saxon Bowker, Roger John Butlin, Craig Samuel Donald, William Mccoull, Thorsten Nowak, Alleyn Plowright
  • 2,3-DIHYDRO-1H-INDENE COMPOUNDS
    Publication number: 20100317593
    Abstract: Provided herein are 2,3-dihydro-1H-indene compounds, methods for making the compounds, pharmaceutical compositions containing the compounds. The described compounds inhibit IAP proteins and can be used to treat various cancers.
    Type: Application
    Filed: June 8, 2010
    Publication date: December 16, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Edward Hennessy, Alexander Hird, Vibha Oza, Jamal Carlos Saeh, Li Sha
  • The Use Of (3-Amino-2-Fluoropropyl) Phosphinic Acid For Treatment Of NERD
    Publication number: 20100317626
    Abstract: The present invention is directed to the use of (3-Amino-2-fluoropropyl)phosphinic acid or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, for the treatment or prevention of non-erosive reflux disease (NERD).
    Type: Application
    Filed: July 24, 2008
    Publication date: December 16, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Goran Hasselgren, Anders Lehmann, Hans Rydholm